Fig. 2: Major observed pre-F substitutions in the Phase 2b and MELODY trials (full cohort). | Nature Communications

Fig. 2: Major observed pre-F substitutions in the Phase 2b and MELODY trials (full cohort).

From: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

Fig. 2: Major observed pre-F substitutions in the Phase 2b and MELODY trials (full cohort).The alternative text for this image may have been generated using AI.

A Location and B frequency. RSV A residues S25, S99, A102, and A103 with substitutions frequencies ≥1–<5% from Phase 2b; S24, S105, and A518 with substitutions frequencies >0–<1% from MELODY; and A103, A107 with substitutions frequencies ≥1–<5% from MELODY are not depicted due to absence or density in PDB ID: 5UDC. RSV B residues A103 with substitutions frequency ≥50% from Phase 2b; T518 with substitutions frequency ≥1–<5% from Phase 2b; N99, and T522 with substitutions frequencies >0–<1% from MELODY; and A103V with substitutions frequency ≥25– < 50% from MELODY are not depicted due to absence or density in PDB ID: 5UDD. F fusion protein, PDB Protein Data Bank, RSV respiratory syncytial virus.

Back to article page